PCM
CNCE

Prelude Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Prelude Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,666
Closed -$16K – 2176
2020
Q3 		$16K Buy
+1,666
New +$16.4K ﹤0.01% 1381
2020
Q1 		– Sell
-2,584
Closed -$24K – 2189
2019
Q4 		$24K Sell
2,584
-916
-26% -$6.49K ﹤0.01% 1546
2019
Q3 		$21K Buy
3,500
+2,696
+335% +$28.6K ﹤0.01% 1385
2019
Q2 		$10K Buy
+804
New +$8.65K ﹤0.01% 1409
2018
Q4 		– Sell
-711
Closed -$11K – 2272
2018
Q3 		$11K Sell
711
-983
-58% -$15.5K ﹤0.01% 1444
2018
Q2 		$29K Buy
+1,694
New +$32.9K ﹤0.01% 1268
2017
Q4 		– Sell
-700
Closed -$10K – 1816
2017
Q3 		$10K Buy
+700
New +$10.2K ﹤0.01% 1439
2017
Q2 		– Sell
-1,000
Closed -$17K – 1930
2017
Q1 		$17K Sell
1,000
-6,100
-86% -$73.2K ﹤0.01% 1297
2016
Q4 		$73K Buy
7,100
+3,900
+122% +$35.6K 0.01% 932
2016
Q3 		$32K Buy
3,200
+700
+28% +$7.65K ﹤0.01% 1204
2016
Q2 		$28K Buy
2,500
+900
+56% +$11.5K ﹤0.01% 1179
2016
Q1 		$22K Sell
1,600
-1,300
-45% -$18.7K ﹤0.01% 1105
2015
Q4 		$55K Buy
+2,900
New +$63K 0.01% 1023
2015
Q1 		– Sell
-1,400
Closed -$19K – 2263
2014
Q4 		$19K Sell
1,400
-1,700
-55% -$22K ﹤0.01% 1748
2014
Q3 		$39K Buy
+3,100
New +$30.1K 0.01% 1480

Other funds holding CNCE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's CNCE Position: Q4 2020 in Review

Prelude Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2020, closing a stake of 1,666 shares — an estimated $16K sold.

Prelude Capital Management first reported a position in CNCE in Q3 2014 and held it in 15 quarters. The position peaked at $73K in Q4 2016. 100 funds tracked by Wall St. Rank hold CNCE as of Q4 2020.

  • Prelude Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1,666 Concert Pharmaceuticals, Inc. shares in Q4 2020, an estimated $16K.
  • Prelude Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 15 quarters.
  • Prelude Capital Management's Concert Pharmaceuticals, Inc. position peaked at $73K in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.